Surgalign Holdings 과거 수익 실적

과거 기준 확인 0/6

Surgalign Holdings의 수입은 연평균 -9.6%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 12%의 비율로 증가했습니다. 매출은 연평균 27.9%의 비율로 감소해 왔습니다.

주요 정보

-9.6%

수익 성장률

0.08%

EPS 성장률

Medical Equipment 산업 성장	8.9%
매출 성장률	-27.9%
자기자본 수익률	n/a
순이익	-64.6%
최근 수익 업데이트	31 Mar 2023

최근 과거 실적 업데이트

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

수익 및 비용 분석

Surgalign Holdings 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OTCPK:SRGA.Q 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 23	78	-50	92	14
31 Dec 22	82	-55	96	16
30 Sep 22	83	-62	99	17
30 Jun 22	84	-61	103	16
31 Mar 22	88	-66	104	15
31 Dec 21	91	-81	104	14
30 Sep 21	95	-152	107	11
30 Jun 21	102	-171	107	10
31 Mar 21	98	-185	113	11
31 Dec 20	102	-194	124	12
30 Sep 20	107	-275	137	14
30 Jun 20	108	-266	144	16
31 Mar 20	75	-264	140	17
31 Dec 19	117	-249	135	17
30 Sep 19	157	-49	128	17
30 Jun 19	197	-29	123	16
31 Mar 19	280	-13	123	15
31 Dec 18	92	-52	98	14
30 Sep 18	280	-14	116	13
30 Jun 18	278	0	114	13
31 Mar 18	280	3	114	13
31 Dec 17	280	3	115	13
30 Sep 17	280	-1	116	14
30 Jun 17	280	-22	117	15
31 Mar 17	275	-22	118	16
31 Dec 16	276	-17	117	16
30 Sep 16	278	-3	115	16
30 Jun 16	278	4	111	16
31 Mar 16	282	10	108	16
31 Dec 15	282	12	107	15
30 Sep 15	277	8	108	16
30 Jun 15	276	7	109	16
31 Mar 15	270	6	109	15
31 Dec 14	263	0	108	16
30 Sep 14	252	-9	105	15
30 Jun 14	242	-19	103	16
31 Mar 14	218	-24	91	16
31 Dec 13	198	-19	82	15
30 Sep 13	182	-8	71	14
30 Jun 13	172	4	60	13
31 Mar 13	175	8	59	13
31 Dec 12	178	8	58	12

양질의 수익: SRGA.Q 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SRGA.Q 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SRGA.Q 은(는) 수익성이 없으며 지난 5년 동안 연간 9.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SRGA.Q 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SRGA.Q 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 10.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SRGA.Q 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Surgalign Holdings 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System

Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego.

Independent Director has left the company

VP, Chief Accounting Officer & Corporate Controller has left the company

Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019)

Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020

Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders

Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares?

Price target lowered to US$5.00

Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021